.Attribute Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients along with HER2+ enhanced breast cancer cells and also active or dependable brain metastases revealed constant intracranial activity and also wide spread efficiency of T-DXd.